Literature DB >> 18327132

Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema.

Kristen L Hartley1, William E Smiddy, Harry W Flynn, Timothy G Murray.   

Abstract

PURPOSE: To evaluate anatomic and visual acuity (VA) results of pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling for diffuse diabetic macular edema (DME), and to review the literature on the topic.
METHODS: Retrospective noncomparative case series of patients who underwent PPV with ILM peeling for diffuse DME between January 1, 2000, and December 1, 2005, performed by three surgeons at Bascom Palmer Eye Institute. Main outcome measures included pre- and postoperative optical coherence tomography (OCT) and visual acuity. Mean follow-up period was 8 months (range, 43 days-2 years).
RESULTS: Twenty-four eyes of 23 patients meeting the criteria were evaluated. Duration of DME ranged from 1 to 93 months. Mean preoperative logMAR vision was 0.782 (range, 0.30-1.82). Mean logMAR visual acuity at final follow-up was 0.771 (range, 0.10-2.00). At last follow-up, 25% of eyes had > or =2 line increase in VA from baseline, 54% of eyes had no improvement in VA, and 21% of eyes had > or =2 line decrease in VA. Of 9 eyes with pre- and postoperative OCT, there was an overall reduction in central macular thickness of 141 microm at postoperative month 3 and 120 microm at last follow-up. Postoperative complications included progression of cataract in 6 (60%) of 10 phakic eyes, postoperative intraocular pressure > or =30 mmHg in 6 (24%) eyes, and postoperative vitreous hemorrhage in 2 (8%) eyes.
CONCLUSIONS: Pars plana vitrectomy with ILM peeling was associated with a reduction in DME when measured by OCT in the majority of eyes, but visual acuity outcomes showed minimal improvement compared to baseline. These results suggest the efficacy of PPV with ILM peeling for eyes with DME has not been well established and should be reserved for therapy with selected cases.

Entities:  

Mesh:

Year:  2008        PMID: 18327132     DOI: 10.1097/IAE.0b013e31816102f2

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  32 in total

1.  Current status in diabetic macular edema treatments.

Authors:  Pedro Romero-Aroca
Journal:  World J Diabetes       Date:  2013-10-15

2.  Three-dimensional imaging of the inner limiting membrane folding on the vitreomacular interface in diabetic macular edema.

Authors:  Sachi Abe; Teiko Yamamoto; Yoshiko Kashiwagi; Eriko Kirii; Sakiko Goto; Hidetoshi Yamashita
Journal:  Jpn J Ophthalmol       Date:  2013-10-11       Impact factor: 2.447

3.  Histopathologic analysis of the internal limiting membrane surgically peeled from eyes with diffuse diabetic macular edema.

Authors:  Kaoru Tamura; Toshiyuki Yokoyama; Nobuyuki Ebihara; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2012-03-23       Impact factor: 2.447

Review 4.  ILM peeling in nontractional diabetic macular edema: review and metanalysis.

Authors:  M Rinaldi; R dell'Omo; F Morescalchi; F Semeraro; E Gambicorti; F Cacciatore; F Chiosi; C Costagliola
Journal:  Int Ophthalmol       Date:  2017-10-31       Impact factor: 2.031

5.  Managing diabetic macular edema: The leading cause of diabetes blindness.

Authors:  Pedro Romero-Aroca
Journal:  World J Diabetes       Date:  2011-06-15

6.  Associated factors and treatment outcome of presumed noninfectious endophthalmitis occurring after intravitreal triamcinolone acetonide injection.

Authors:  Seong Joon Ahn; Tae Wan Kim; Jeeyun Ahn; Jang Won Huh; Hyeong Gon Yu; Hum Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-22       Impact factor: 3.117

7.  Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes.

Authors:  Norihito Doi; Taiji Sakamoto; Yasushi Sonoda; Miho Yasuda; Koji Yonemoto; Noboru Arimura; Eisuke Uchino; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-19       Impact factor: 3.117

Review 8.  Management of diabetic macular edema in Japan: a review and expert opinion.

Authors:  Hiroko Terasaki; Yuichiro Ogura; Shigehiko Kitano; Taiji Sakamoto; Toshinori Murata; Akito Hirakata; Tatsuro Ishibashi
Journal:  Jpn J Ophthalmol       Date:  2017-12-05       Impact factor: 2.447

9.  A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.

Authors: 
Journal:  Ophthalmology       Date:  2008-07-26       Impact factor: 12.079

10.  Diabetic macular edema.

Authors:  Einar Stefánsson
Journal:  Saudi J Ophthalmol       Date:  2009-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.